$1.3 Billion is the total value of Kynam Capital Management, LP's 26 reported holdings in Q2 2024. The portfolio turnover from Q1 2024 to Q2 2024 was 30.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NTRA | Buy | NATERA INC | $218,140,242 | +19.3% | 2,014,408 | +0.7% | 16.83% | -12.1% |
| VRTX | Buy | VERTEX PHARMACEUTICALS INCput | $154,677,600 | +270.0% | 330,000 | +230.0% | 11.93% | +172.7% |
| CLDX | Buy | CELLDEX THERAPEUTICS INC NEW | $125,425,669 | +3.1% | 3,388,967 | +16.9% | 9.68% | -24.0% |
| SNDX | Buy | SYNDAX PHARMACEUTICALS INC | $117,473,830 | -12.8% | 5,722,057 | +1.1% | 9.06% | -35.7% |
| SPY | New | SPDR S&P 500 ETF TRput | $109,100,000 | – | 200,000 | +100.0% | 8.42% | – |
| DVAX | Buy | DYNAVAX TECHNOLOGIES CORP | $79,537,171 | +51.2% | 7,082,562 | +67.1% | 6.14% | +11.4% |
| COGT | Buy | COGENT BIOSCIENCES INC | $78,065,046 | +36.7% | 9,260,385 | +8.9% | 6.02% | +0.7% |
| INSM | New | INSMED INCcall | $67,000,000 | – | 1,000,000 | +100.0% | 5.17% | – |
| PCVX | Buy | VAXCYTE INC | $56,877,152 | +11.8% | 753,240 | +1.1% | 4.39% | -17.6% |
| VERA | Buy | VERA THERAPEUTICS INCcl a | $55,849,944 | -15.2% | 1,543,669 | +1.1% | 4.31% | -37.5% |
| BCRX | Buy | BIOCRYST PHARMACEUTICALS INC | $54,549,068 | +64.5% | 8,826,710 | +35.2% | 4.21% | +21.3% |
| PTGX | Sell | PROTAGONIST THERAPEUTICS INC | $27,720,000 | -16.3% | 800,000 | -30.1% | 2.14% | -38.3% |
| 2SEVENTY BIO INC | $22,922,226 | -28.0% | 5,953,825 | 0.0% | 1.77% | -47.0% | ||
| VRDN | Buy | VIRIDIAN THERAPEUTICS INC | $22,767,500 | +871.2% | 1,750,000 | +1207.2% | 1.76% | +616.7% |
| WVE | Buy | WAVE LIFE SCIENCES LTD | $19,837,850 | -18.2% | 3,975,521 | +1.1% | 1.53% | -39.7% |
| TVTX | Buy | TRAVERE THERAPEUTICS INC | $16,618,037 | +7.8% | 2,021,659 | +1.1% | 1.28% | -20.6% |
| LQDA | Sell | LIQUIDIA CORPORATION | $10,998,888 | -66.8% | 916,574 | -59.2% | 0.85% | -75.6% |
| IRWD | Buy | IRONWOOD PHARMACEUTICALS INC | $10,705,129 | -24.4% | 1,641,891 | +1.0% | 0.83% | -44.2% |
| ALNY | New | ALNYLAM PHARMACEUTICALS INCput | $10,449,000 | – | 43,000 | +100.0% | 0.81% | – |
| Buy | TYRA BIOSCIENCES INC | $9,061,773 | +7.3% | 566,715 | +10.0% | 0.70% | -20.9% | |
| AMRN | Buy | AMARIN CORP PLCspons adr new | $8,363,211 | -21.9% | 12,155,830 | +1.1% | 0.64% | -42.5% |
| New | BURNING ROCK BIOTECH LTDsponsored ads | $6,283,880 | – | 974,668 | +100.0% | 0.48% | – | |
| STRO | Buy | SUTRO BIOPHARMA INC | $5,929,391 | -47.6% | 2,023,683 | +1.1% | 0.46% | -61.4% |
| Buy | ACELYRIN INC | $3,666,077 | +37.0% | 831,310 | +109.7% | 0.28% | +1.1% | |
| Buy | CARIBOU BIOSCIENCES INC | $2,700,591 | -50.8% | 1,646,702 | +54.1% | 0.21% | -63.8% | |
| New | CG ONCOLOGY INC | $1,701,970 | – | 53,911 | +100.0% | 0.13% | – | |
| BNR | Exit | BURNING ROCK BIOTECH LTDsponsored ads | $0 | – | -9,640,914 | -100.0% | -0.74% | – |
| CORT | Exit | CORCEPT THERAPEUTICS INCput | $0 | – | -585,900 | -100.0% | -1.54% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2024-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| SYNDAX PHARMACEUTICALS INC | 11 | Q2 2024 | 14.1% |
| CELLDEX THERAPEUTICS INC NEW | 11 | Q2 2024 | 14.4% |
| VAXCYTE INC | 11 | Q2 2024 | 10.9% |
| VERA THERAPEUTICS INC | 11 | Q2 2024 | 6.9% |
| TRAVERE THERAPEUTICS INC | 11 | Q2 2024 | 7.6% |
| VIRIDIAN THERAPEUTICS INC | 11 | Q2 2024 | 4.6% |
| LIQUIDIA CORPORATION | 11 | Q2 2024 | 3.6% |
| WAVE LIFE SCIENCES LTD | 11 | Q2 2024 | 3.7% |
| AMARIN CORP PLC | 11 | Q2 2024 | 4.0% |
| NATERA INC | 10 | Q2 2024 | 21.7% |
View Kynam Capital Management, LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-08-30 |
| 13F-HR | 2024-08-14 |
| 13F-HR | 2024-05-15 |
| SC 13G/A | 2024-03-08 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
View Kynam Capital Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.